Home Investors

Kiadis Pharma’s primary objective is to become a leading biopharmaceutical company focused on developing and commercializing therapeutic products in cell-based immunotherapy. We aim to develop products that provide safer and more efficacious treatment options for cancer and blood disorder patients, improving their survival rate and quality of life.

Media and Investor Contact

Mary-Jane Elliott, Lindsey Neville, Hendrik Thys
Consilium Strategic Communications

Tel: +44 (0) 203 709 5708
kiadis@consilium-comms.com

Stock Information

Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015 under the symbol KDS.

Financial Calendar
  • Mar 31 2017
    Full Year Results 2016
  • Aug 25 2017
    Half Year Results 2017